Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2014, Article ID 184297, 6 pages
http://dx.doi.org/10.1155/2014/184297
Research Article

Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?

1BC Cancer Agency Radiation Therapy Program, BC Cancer Agency, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC, Canada V5Z 4E6
2University of British Columbia, 2329 West Mall, Vancouver, BC, Canada V6T 1Z4
3Cancer Surveillance & Outcomes, Population Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, Canada V5Z 4E6

Received 2 November 2013; Revised 13 January 2014; Accepted 25 January 2014; Published 3 March 2014

Academic Editor: Katsuto Shinohara

Copyright © 2014 J. Caon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. e-CPS English, “e-CPS : Drug Monographs : HMG-CoA Reductase Inhibitors (CPhA Monograph),” 2011, https://www.e-therapeutics.ca/cps.showMonograph.action?simpleMonographId=m250500.
  2. R. J. Hamilton, K. C. Goldberg, E. A. Platz, and S. J. Freedland, “The influence of statin medications on prostate-specific antigen levels,” Journal of the National Cancer Institute, vol. 100, no. 21, pp. 1511–1518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Y. Oh, E. J. Lee, S. Yoon, B. H. Chung, K. S. Cho, and S. J. Hong, “Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction,” The Prostate, vol. 67, no. 10, pp. 1061–1069, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Yang, M. Egger, R. Plattner, H. Klocker, and I. E. Eder, “Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells,” Urology, vol. 77, no. 6, pp. 1508.e1–1508.e7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Yokomizo, M. Shiota, E. Kashiwagi et al., “Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells,” The Prostate, vol. 71, no. 3, pp. 298–304, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. D. J. Mener, “Prostate specific antigen reduction following statin therapy: mechanism of action and review of the literature,” IUBMB Life, vol. 62, no. 8, pp. 584–590, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. e-CPS English, “e-CPS : Drug Monographs : Aspirin,” 2011, https://www.e-therapeutics.ca/cps.showMonograph.action?simpleMonographId=m069600.
  8. R. E. Harris, J. Beebe-Donk, H. Doss, and D. Burr Doss, “Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review),” Oncology Reports, vol. 13, no. 4, pp. 559–583, 2005. View at Google Scholar · View at Scopus
  9. A. Falanga, M. Marchetti, A. Vignoli, and D. Balducci, “Clotting mechanisms and cancer: implications in thrombus formation and tumor progression,” Clinical Advances in Hematology & Oncology, vol. 1, no. 11, pp. 673–678, 2003. View at Google Scholar · View at Scopus
  10. T. Veitonmaki, T. L. Tammela, A. Auvinen, and T. J. Murtola, “Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level,” European Journal of Cancer, vol. 49, no. 4, pp. 938–945, 2013. View at Publisher · View at Google Scholar
  11. P. K. Dhillon, S. A. Kenfield, M. J. Stampfer, E. L. Giovannucci, and J. M. Chan, “Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort,” Cancer Prevention Research, vol. 5, no. 10, pp. 1223–1228, 2012. View at Google Scholar
  12. K. S. Choe, D. Correa, A. B. Jani, and S. L. Liauw, “The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy,” Cancer, vol. 116, no. 7, pp. 1820–1826, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Gutt, N. Tonlaar, R. Kunnavakkam, T. Karrison, R. R. Weichselbaum, and S. L. Liauw, “Statin use and risk of prostate cancer recurrence in men treated with radiation therapy,” Journal of Clinical Oncology, vol. 28, no. 16, pp. 2653–2659, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. A. Kollmeier, M. S. Katz, K. Mak et al., “Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy,” International Journal of Radiation Oncology, Biology, Physics, vol. 79, no. 3, pp. 713–718, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. E. R. Mora, J. A. L. Garin, O. B. Gali, A. F. Comalat, L. F. Ciutat, and O. A. Toro, “The impact of statins use in clinically localized prostate cancer treated with radical prostatectomy,” Actas Urologicas Espanolas, vol. 33, no. 4, pp. 351–355, 2009. View at Google Scholar · View at Scopus
  16. D. E. Soto, S. Daignault, H. M. Sandler, and M. E. Ray, “No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer,” Urology, vol. 73, no. 1, pp. 158–162, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. V. D'Amico, “Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer,” Journal of Clinical Oncology, vol. 28, no. 16, pp. 2651–2652, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Extermann, “Measuring comorbidity in older cancer patients,” European Journal of Cancer, vol. 36, no. 4, pp. 453–471, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. M. E. Charlson, P. Pompei, K. A. Ales, and C. R. MacKenzie, “A new method of classifying prognostic comorbidity in longitudinal studies: development and validation,” Journal of Chronic Diseases, vol. 40, no. 5, pp. 373–383, 1987. View at Google Scholar · View at Scopus
  20. J. P. Fine and R. J. Gray, “A proportional hazards model for the subdistribution of a competing risk,” Journal of the American Statistical Association, vol. 94, no. 446, pp. 496–509, 1999. View at Google Scholar · View at Scopus
  21. R. H. Breau, R. J. Karnes, D. J. Jacobson et al., “The association between statin use and the diagnosis of prostate cancer in a population based cohort,” The Journal of Urology, vol. 184, no. 2, pp. 494–499, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. E. A. Platz, M. F. Leitzmann, K. Visvanathan et al., “Statin drugs and risk of advanced prostate cancer,” Journal of the National Cancer Institute, vol. 98, no. 24, pp. 1819–1825, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Shannon, S. Tewoderos, M. Garzotto et al., “Statins and prostate cancer risk: a case-control study,” American Journal of Epidemiology, vol. 162, no. 4, pp. 318–325, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Blais, A. Desgagné, and J. LeLorier, “3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the risk of cancer: a nested case-control study,” Archives of Internal Medicine, vol. 160, no. 15, pp. 2363–2368, 2000. View at Google Scholar · View at Scopus
  25. S. Friis, A. H. Poulsen, S. P. Johnsen et al., “Cancer risk among statin users: a population-based cohort study,” International Journal of Cancer, vol. 114, no. 4, pp. 643–647, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. M. R. Graaf, A. B. Beiderbeck, A. C. G. Egberts, D. J. Richel, and H.-J. Guchelaar, “The risk of cancer in users of statins,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2388–2394, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Tagalakis, H. Tamim, M. Blostein, J.-P. Collet, J. A. Hanley, and S. R. Kahn, “Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study,” The Lancet Oncology, vol. 8, no. 5, pp. 395–402, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Schulman and P. Lindmarker, “Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism,” The New England Journal of Medicine, vol. 342, no. 26, pp. 1953–1958, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. E. J. Jacobs, M. J. Thun, E. B. Bain, C. Rodriguez, S. J. Henley, and E. E. Calle, “A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence,” Journal of the National Cancer Institute, vol. 99, no. 8, pp. 608–615, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. L. R. Zacharski, W. G. Henderson, F. R. Rickles et al., “Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75,” Cancer, vol. 53, no. 10, pp. 2046–2052, 1984. View at Google Scholar · View at Scopus
  31. R. J. Hamilton, L. L. Banez, W. J. Aronson et al., “Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database,” Cancer, vol. 116, no. 14, pp. 3389–3398, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. L. S. Krane, S. A. Kaul, H. J. Stricker, J. O. Peabody, M. Menon, and P. K. Agarwal, “Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen,” The Journal of Urology, vol. 183, no. 1, pp. 118–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. A. Moyad, G. S. Merrick, W. M. Butler et al., “Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer,” Urology, vol. 66, no. 6, pp. 1150–1154, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. J. H. Ku, C. W. Jeong, Y. H. Park, M. C. Cho, C. Kwak, and H. H. Kim, “Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients,” Prostate Cancer and Prostatic Diseases, vol. 14, no. 1, pp. 63–68, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. T. J. Murtola, “Statin use is associated with improved prostate cancer survival: is it time for a clinical trial?” Expert Review of Anticancer Therapy, vol. 10, no. 10, pp. 1563–1567, 2010. View at Google Scholar